Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate

A. Licchetta; Pierpaolo Correale; C. Migali; C. Remondo; E. Francini; A. Pascucci; A. Magliocca; A. Guarnieri; V. Savelli; A. Piccolomini; A. F. Carli; G. Francini

doi:10.1179/joc.2010.22.3.201

Back

Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate

Journal article

Peer reviewed

Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate

A. Licchetta, Pierpaolo Correale, C. Migali, C. Remondo, E. Francini, A. Pascucci, A. Magliocca, A. Guarnieri, V. Savelli, A. Piccolomini, …

Journal of chemotherapy (Florence), Vol.22(3), pp.201-204

06/01/2010

DOI: 10.1179/joc.2010.22.3.201

PMID: 20566427

View Online

Abstract

Metronomic chemotherapy is an anticancer strategy which uses conventional cytotoxic drugs administered at very low dose in close intervals. We have designed a phase ii trial to investigate the safety and antitumor activity of the newest metronomic chemo-hormonal-therapy with daily cyclophosphamide and twice daily megestrol acetate (MCM regimen) in patients with metastatic pretreated breast cancer. Twenty-nine pretreated post-menopausal patients with multiple metastatic sites were enrolled. Four patients had a triple negative status, nineteen a positive hormonal ER and PGR status, and three ERB-B2 over-expression. Patients received treatment with cyclophosphamide (50 mg/daily day 1-21/q28) and fractionated megestrol acetate (80 mg twice a day). The overall objective response rate was 31.0%, disease control rate 41.3%, mean time to tumor progression 7.4 months (CI 95%, 3.8-10.88, range 1-48 months) and mean overall survival 13.4 months (CI 95%, 7.24-17.18, range 1-53 months). The MCM regimen was active and well tolerated.

Megestrol acetate

Metastatic breast cancer

Metronomic chemo-hormonal-therapy

Details

Title: Subtitle: Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate
Creators: A. Licchetta - University of Siena
Pierpaolo Correale - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
C. Migali - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
C. Remondo - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
E. Francini - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
A. Pascucci - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
A. Magliocca - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
A. Guarnieri - Department of Surgery, Siena University School of Medicine, Italy
V. Savelli - Department of Surgery, Siena University School of Medicine, Italy
A. Piccolomini - Department of Surgery, Siena University School of Medicine, Italy
A. F. Carli - Department of Surgery, Siena University School of Medicine, Italy
G. Francini - Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
Resource Type: Journal article
Publication Details: Journal of chemotherapy (Florence), Vol.22(3), pp.201-204
DOI: 10.1179/joc.2010.22.3.201
PMID: 20566427
NLM abbreviation: J Chemother
ISSN: 1120-009X
eISSN: 1973-9478
Number of pages: 4
Language: English
Date published: 06/01/2010
Academic Unit: Internal Medicine
Record Identifier: 9985221146802771

Metrics

2 Record Views

23 Times Cited - Web of Science